Phase I trial of echinomycin (NSC 526417), a bifunctional intercalating agent, administered by 24-hour continuous infusion

Echinomycin protects mice against relapsed acute myeloid leukemia without adverse effect on hematopoietic stem cells

“…[38][39][40][41][42][43][44][45] In fact, dose escalation studies indicated that grade I toxicity was observed starting after doses of 180 mg/m 2 , with no toxicity found at doses of 60 and 120 mg/m 2 . 46 By showing that a low dose of echinomycin (30 mg/m 2 ) eliminates AML LICs without a significant effect on the HSCs, our data, along with our recent data on primary AML samples, 17 provide a foundation for further clinical development of the drug for treatment of both primary and relapsed AML.…”

Echinomycin protects mice against relapsed acute myeloid leukemia without adverse effect on hematopoietic stem cells

“…[38][39][40][41][42][43][44][45] In fact, dose escalation studies indicated that grade I toxicity was observed starting after doses of 180 mg/m 2 , with no toxicity found at doses of 60 and 120 mg/m 2 . 46 By showing that a low dose of echinomycin (30 mg/m 2 ) eliminates AML LICs without a significant effect on the HSCs, our data, along with our recent data on primary AML samples, 17 provide a foundation for further clinical development of the drug for treatment of both primary and relapsed AML.…”

Synthesis and biological evaluation of echinomycin analogues as potential colon cancer agent

“…As previously noted, human clinical trials of 1 have suggested that echinomycin at doses ranging from 1200 to 2128 μg/m 2 given intravenously is toxic. However, there was no observed toxicity at the lower doses of 60 and 120 μg/m 2 30 . Sulfide 3 retains the cytotoxic activity of 1 both in vitro and in vivo and is more accessible and scalable than 1 .…”

Quinomycin A reduces cyst progression in polycystic kidney disease

“…[32][33][34][35][36][37][38] Doses of 60-120 mg/ m 2 were found to have no toxicity. 39 Recent studies in mice indicate that low doses (eg, 10 μg/kg body weight) of Quinomycin A are not toxic to normal cell hematopoiesis and selectively targets cancerous cells in acute myelocytic leukemia and bladder cancer. 13,14 To further combat the F I G U R E 5 Quinomycin A targets the Notch signaling pathway in PKD.…”

“…These toxicities were attributed to the higher dose of 180 mg/m 2 of Quinomycin A 32‐38 . Doses of 60‐120 mg/m 2 were found to have no toxicity 39 . Recent studies in mice indicate that low doses (eg, 10 μg/kg body weight) of Quinomycin A are not toxic to normal cell hematopoiesis and selectively targets cancerous cells in acute myelocytic leukemia and bladder cancer 13,14 .…”

Echinomycin protects mice against relapsed acute myeloid leukemia without adverse effect on hematopoietic stem cells

“…[38][39][40][41][42][43][44][45] In fact, dose escalation studies indicated that grade I toxicity was observed starting after doses of 180 mg/m 2 , with no toxicity found at doses of 60 and 120 mg/m 2 . 46 By showing that a low dose of echinomycin (30 mg/m 2 ) eliminates AML LICs without a significant effect on the HSCs, our data, along with our recent data on primary AML samples, 17 provide a foundation for further clinical development of the drug for treatment of both primary and relapsed AML.…”

Synthesis and biological evaluation of echinomycin analogues as potential colon cancer agent

“…As previously noted, human clinical trials of 1 have suggested that echinomycin at doses ranging from 1200 to 2128 μg/m 2 given intravenously is toxic. However, there was no observed toxicity at the lower doses of 60 and 120 μg/m 2 30 . Sulfide 3 retains the cytotoxic activity of 1 both in vitro and in vivo and is more accessible and scalable than 1 .…”

Quinomycin A reduces cyst progression in polycystic kidney disease

“…[32][33][34][35][36][37][38] Doses of 60-120 mg/ m 2 were found to have no toxicity. 39 Recent studies in mice indicate that low doses (eg, 10 μg/kg body weight) of Quinomycin A are not toxic to normal cell hematopoiesis and selectively targets cancerous cells in acute myelocytic leukemia and bladder cancer. 13,14 To further combat the F I G U R E 5 Quinomycin A targets the Notch signaling pathway in PKD.…”

“…These toxicities were attributed to the higher dose of 180 mg/m 2 of Quinomycin A 32‐38 . Doses of 60‐120 mg/m 2 were found to have no toxicity 39 . Recent studies in mice indicate that low doses (eg, 10 μg/kg body weight) of Quinomycin A are not toxic to normal cell hematopoiesis and selectively targets cancerous cells in acute myelocytic leukemia and bladder cancer 13,14 .…”

Echinomycin protects mice against relapsed acute myeloid leukemia without adverse effect on hematopoietic stem cells

“…[38][39][40][41][42][43][44][45] In fact, dose escalation studies indicated that grade I toxicity was observed starting after doses of 180 mg/m 2 , with no toxicity found at doses of 60 and 120 mg/m 2 . 46 By showing that a low dose of echinomycin (30 mg/m 2 ) eliminates AML LICs without a significant effect on the HSCs, our data, along with our recent data on primary AML samples, 17 provide a foundation for further clinical development of the drug for treatment of both primary and relapsed AML.…”

Synthesis and biological evaluation of echinomycin analogues as potential colon cancer agent

“…As previously noted, human clinical trials of 1 have suggested that echinomycin at doses ranging from 1200 to 2128 μg/m 2 given intravenously is toxic. However, there was no observed toxicity at the lower doses of 60 and 120 μg/m 2 30 . Sulfide 3 retains the cytotoxic activity of 1 both in vitro and in vivo and is more accessible and scalable than 1 .…”

Quinomycin A reduces cyst progression in polycystic kidney disease

“…[32][33][34][35][36][37][38] Doses of 60-120 mg/ m 2 were found to have no toxicity. 39 Recent studies in mice indicate that low doses (eg, 10 μg/kg body weight) of Quinomycin A are not toxic to normal cell hematopoiesis and selectively targets cancerous cells in acute myelocytic leukemia and bladder cancer. 13,14 To further combat the F I G U R E 5 Quinomycin A targets the Notch signaling pathway in PKD.…”

“…These toxicities were attributed to the higher dose of 180 mg/m 2 of Quinomycin A 32‐38 . Doses of 60‐120 mg/m 2 were found to have no toxicity 39 . Recent studies in mice indicate that low doses (eg, 10 μg/kg body weight) of Quinomycin A are not toxic to normal cell hematopoiesis and selectively targets cancerous cells in acute myelocytic leukemia and bladder cancer 13,14 .…”